 |
|
June 1, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
|
BIG4BIO
WEEKLY CEO Q&A:
Robin Toft, CEO, Curebound |
| In
this Q&A, Robin talks about her career
pivot into the nonprofit sector, the
collaborative research model that sets
Curebound apart, the growing role of
philanthropic capital to fill funding
gaps, and what it takes to build both a
high-performing team and a research
accelerator with staying power. More |
|
|
- Actinium Pharmaceuticals: Receives Two
Patent Allowances Spanning Its Actimab-A and
Iomab-ACT Programs More
- Axsome Therapeutics: Partners With the
Headache Alliance to Highlight the Impact of
Migraine During Migraine and Headache
Awareness Month More
- Bayer: Shares New Findings for NUBEQA
(darolutamide) Regarding Cognitive Decline in
Men With Advanced Prostate Cancer Compared to
Enzalutamide in Phase II ARACOG Head-to-Head
Trial
More
- Bristol Myers Squibb and BioNTech:
Global Data for PD-L1xVEGF-A Bispecific
Pumitamig Shows Encouraging Efficacy in
Patients With Non-Small Cell Lung Cancer in
ROSETTA Lung-02 Trial More
More
- Bristol Myers Squibb: Opdivo (nivolumab) in
Combination With AVD Receives Expanded EU
Label With Approval in Frontline Advanced
Classical Hodgkin Lymphoma More
- Bristol Myers Squibb: U.S. Food and Drug
Administration Accepts for Priority Review
Supplemental New Drug Application for Camzyos
(mavacamten) to Treat Adolescents With
Symptomatic Obstructive Hypertrophic
Cardiomyopathy (oHCM) More
- Citius Oncology: Phase 1 Data in an
Investigator-Initiated Study of LYMPHIR
(denileukin diftitox-cxdl) in Combination With
Pembrolizumab in Recurrent or Refractory
Gynecologic Malignancies More
- Holmusk: Expands NeuroBlu to 46 Million
Patients, Adding Depth and Biomarker Data
Across Neurology and Behavioral Health More
- Kamada: FDA Approval of its New In-House
Rabies Virus Neutralization Testing Laboratory
More
- OS Therapies: Publication of Four Articles
on OST-HER2 and Osteosarcoma in Drug Discovery
World More
- Pfizer: BRAFTOVI Regimen Nearly
Doubles Median Progression-Free Survival in
Metastatic Colorectal Cancer More
- Pfizer: TALZENNA Plus XTANDI
Improves Radiographic Progression-Free
Survival by More Than 50% in Metastatic
Prostate Cancer
More
More
- TG Therapeutics: Publication of Post-Hoc
Data From the Phase 3 ULTIMATE I & II
Trials in Treatment Naive Patients With
Relapsing Forms of MS Published in Frontiers
in Immunology More
- Whitehawk Therapeutics: Real‑World Analysis
Confirming SEZ6 as a Highly Expressed,
Clinically Relevant Target for SCLC and Other
Neuroendocrine Tumors at ASCO 2026 More
|
|
- Beyond Air: Receives Nasdaq Hearing Panel
Decision Granting Continued Listing
More
- Celularity: Receives Nasdaq Notice Regarding
Form 10-Q More
- From Seed to Series C: What Investors Look
for Beyond the Science More
- More on Pfizer Committing $650M Cash,
$10.5Bn Total to China’s Innovent for Cancer
Meds More
More
More
More*
- The Pershing Square Foundation: Its 2026
Lotus Award Recipients More
|
|
- ASCO: Sac-TMT’s Massive Phase 3 Program Has
a Jarring Gap. Does Merck Plan to Close It? More
- Big4Bio CEO Weekly Q&A: Robin
Toft, CEO, Curebound More
- Biotech Hangout: Episode 184 Podcast
- Engineered Enzymes Streamline Synthesis of
an Oral Cholesterol Drug More
- How Schmidt Sciences Is Building the Sensors
Biomanufacturing Never Had More
- More on Bristol Myers Unveiling Data
for One of Its Next-Gen Blood Cancer Drugs More
More* More*
- More on Merck Winning FDA Breakthrough
Therapy Designation for Calderasib More*
- Psychedelic-Assisted Therapies Get a Boost,
but Systems Struggle to Play Catch-Up More
- Subscribe to LifeSci Startup for
Updates on US Startups More
- World MS Day Special: Immunic
Reveals New Hope for Progressive MS Podcast
|
|
- AI in Biotech: The New Frontier for
Leadership & Strategy More
- David Chang to Hand Over the Reins at
Allogene; Ex-Esperion CEO Gets Started at
Phlow More*
- 11 Companies Hiring in New Jersey Now More
- Empowering Students Through STEM: A
Conversation With Massachusetts Science &
Engineering Fair Executive Director Helen
Rosenfeld More
- Hiring Outlook: Job Opportunities on
BioSpace Rise YOY, but Layoffs Affect
Thousands More
- More Than Executive Search: Building
Leadership for Every Stage of Growth More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: NYC Life Science Company
Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:NYC,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
